Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform

Medtronic plc MDT presented five-year clinical data for CoreValve and Evolut transcatheter aortic valve implantation (TAVI) platforms at the 33rd Transcatheter Cardiovascular Therapeutics (TCT) conference.
The trial evaluated two early valve generations across various valve sizes in 864 intermediate-risk symptomatic severe aortic stenosis patients.
Patients in the TAVR arm were compared to 796 intermediate-risk patients who were randomized to open-heart surgery.
Data showed from the trial demonstrated that the hemodynamic (blood flow) benefits of the CoreValve and Evolut systems were maintained at five years with a favorable safety profile and stable valve performance.
At five years, rates of all-cause mortality were similar between TAVR with the CoreValve/Evolut platform and surgical aortic valve replacement (SAVR) (30.0% for TAVR versus 28.7% for SAVR), while rates of disabling stroke were also similar (4.1% for TAVR versus 5.8% for SAVR).
The TAVR arm continued to demonstrate durable valve longevity at five years. Additionally, valve thrombosis remained low out to five years for both TAVR and SAVR.
Price Action: MDT shares are up 2.30% at $123.47 during the market session on the last check Friday.